Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy

Heart Failure Clinical Trial

— ASTRAL-4LV  

Official title:

Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04463641
• Other study ID #: LAXI01
• Status: Active, not recruiting
• Phase: N/A
• Start date: December 3, 2020
• Est. completion date: December 2027

Study information

• Verified date: January 2024
• Source: MicroPort CRM
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to assess the chronic safety and performance of the Axone left ventricular (LV) micro-lead.

Description:

This is a interventional, pivotal, prospective, single arm, open label, multicenter, international trial.

The device under investigation is the Axone system, consisting of:

• Axone 4LV: an ultrathin, lumenless, quadripolar, IS4-compatible lead designed for left ventricular pacing for cardiac resynchronization therapy (CRT).

• Axone µGuide: a dedicated, permanently implantable micro catheter designed for implantation of the Axone 4LV lead.

The primary endpoint data will be used to support CE marking of the Axone system.

The primary endpoints will be evaluated at 6 months post-implantation. Subjects will be followed-up at 6 weeks, 3 months, 6 months, 12 months post-implantation, then yearly until 4 years post-implantation.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 92
• Est. completion date: December 2027
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Indication for cardiac resynchronization therapy-defibrillator (CRT-D) device implant according to the latest ESC (European Society of Cardiology) guidelines

• De-novo implant of a Platinium 4LV CRT-D device (or any newer 4LV CRT-D model manufactured by MicroPort CRM)

• Reviewed, signed and dated informed consent form

Exclusion Criteria:

• LV lead previous implant attempt

• Upgrade to CRT from a previously implanted pacemaker or implantable cardioverter-defibrillator (ICD), or CRT device replacement

• Known allergy to contrast media used for imaging during cardiac catheterization

• Tricuspid valvular disease or any type of tricuspid replacement heart valve (mechanical or tissue)

• Severe renal failure (creatinine clearance according to the Modification of Diet in Renal Disease (MDRD) formula < 30ml/min/m²)

• Active myocarditis

• Stroke, myocardial infarction or cardiac revascularization within 40 days prior to implant

• Previous heart transplant or currently on heart transplant list

• Life expectancy less than 1 year

• Already included in another clinical study that could confound the results of this study

• Pre-menopausal women / women in childbearing age, including pregnant and breastfeeding women

• Less than 18 years old or under guardianship

• Incapacitated subject, inability to understand the purpose of the study, or to meet follow-up visits at the implanting site as defined in the protocol

• Diagnosis of drug addiction (substance use disorder)

Related Conditions & MeSH terms

• Cardiac Resynchronization Therapy
• Heart Failure

Intervention

Device:
• Implantation of the Axone 4LV Lead
Implantation of the Axone 4LV Lead

Locations

Country	Name	City	State
Austria	Kepler Universitätsklinikum	Linz
France	CH Annecy Genevois	Annecy
France	CHRU Hopital Trousseau	Chambray-lès-Tours
France	CHU de Clermont-Ferrand	Clermont-Ferrand
France	CHU Grenoble	Grenoble
France	CHRU de Lille - Hôpital Cardiologique	Lille
France	CHU Pontchaillou	Rennes
France	CHU de Rouen	Rouen
France	CHU Toulouse	Toulouse
Germany	Universitätsklinikum Hamburg Eppendorf	Hamburg
Germany	Universitätsklinikum Heidelberg	Heidelberg
Germany	Universitätsklinikum Schleswig-Holstein Campus Kiel	Kiel
Italy	ASST Spedali Civili di Brescia	Brescia
Italy	Ospedale Pellegrini	Naples
Italy	Ospedale Policlinico Federico II	Naples
Netherlands	Isala Klinieken	Zwolle
Portugal	Centro Hospitalar Universitário Lisboa Norte - Hospital de Santa Maria	Lisbon
Portugal	Centro Hospitalar Universitário do Porto	Porto
Spain	Hospital Universitario General de Alicante	Alicante
Spain	Hospital Universitario La Fe	Valencia
Spain	Hospital Álvaro Cunqueiro	Vigo

Sponsors (1)

Lead Sponsor	Collaborator
MicroPort CRM

Countries where clinical trial is conducted

Austria,  France,  Germany,  Italy,  Netherlands,  Portugal,  Spain, 

References & Publications (18)

Antoniadis AP, Behar JM, Sieniewicz B, Gould J, Niederer S, Rinaldi CA. A comparison of the different features of quadripolar left ventricular pacing leads to deliver cardiac resynchronization therapy. Expert Rev Med Devices. 2017 Sep;14(9):697-706. doi: 10.1080/17434440.2017.1369404. Epub 2017 Aug 23. — View Citation

Auricchio A, Heggermont WA. Technology Advances to Improve Response to Cardiac Resynchronization Therapy: What Clinicians Should Know. Rev Esp Cardiol (Engl Ed). 2018 Jun;71(6):477-484. doi: 10.1016/j.rec.2018.01.006. Epub 2018 Feb 14. English, Spanish. — View Citation

Bonadei I, Vizzardi E, Gorga E, Carubelli V, Pagnoni M, Sciatti E, Raweh A, Cerini M, Bontempi L, Curnis A, Metra M. Role of the old and new echocardiographic technologies in cardiac resynchronization therapy. Minerva Cardioangiol. 2016 Oct;64(5):572-80. Epub 2015 Jun 23. — View Citation

Butter C, Auricchio A, Stellbrink C, Fleck E, Ding J, Yu Y, Huvelle E, Spinelli J; Pacing Therapy for Chronic Heart Failure II Study Group. Effect of resynchronization therapy stimulation site on the systolic function of heart failure patients. Circulation. 2001 Dec 18;104(25):3026-9. doi: 10.1161/hc5001.102229. — View Citation

Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14;352(15):1539-49. doi: 10.1056/NEJMoa050496. Epub 2005 Mar 7. — View Citation

Crossley GH, Biffi M, Johnson B, Lin A, Gras D, Hussin A, Cuffio A, Collier JL, El-Chami M, Li S, Holloman K, Exner DV. Performance of a novel left ventricular lead with short bipolar spacing for cardiac resynchronization therapy: primary results of the Attain Performa quadripolar left ventricular lead study. Heart Rhythm. 2015 Apr;12(4):751-8. doi: 10.1016/j.hrthm.2014.12.019. Epub 2014 Dec 19. — View Citation

Daubert C, Behar N, Martins RP, Mabo P, Leclercq C. Avoiding non-responders to cardiac resynchronization therapy: a practical guide. Eur Heart J. 2017 May 14;38(19):1463-1472. doi: 10.1093/eurheartj/ehw270. — View Citation

Healey JS, Hohnloser SH, Exner DV, Birnie DH, Parkash R, Connolly SJ, Krahn AD, Simpson CS, Thibault B, Basta M, Philippon F, Dorian P, Nair GM, Sivakumaran S, Yetisir E, Wells GA, Tang AS; RAFT Investigators. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail. 2012 Sep 1;5(5):566-70. doi: 10.1161/CIRCHEARTFAILURE.112.968867. Epub 2012 Aug 14. — View Citation

Leclercq C, Burri H, Curnis A, Delnoy PP, Rinaldi CA, Sperzel J, Lee K, Calo L, Vicentini A, Concha JF, Thibault B. Cardiac resynchronization therapy non-responder to responder conversion rate in the more response to cardiac resynchronization therapy with MultiPoint Pacing (MORE-CRT MPP) study: results from Phase I. Eur Heart J. 2019 Sep 14;40(35):2979-2987. doi: 10.1093/eurheartj/ehz109. — View Citation

Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008 Dec 2;52(23):1834-1843. doi: 10.1016/j.jacc.2008.08.027. Epub 2008 Nov 7. — View Citation

Macias A, Gavira JJ, Alegria E, Azcarate PM, Barba J, Garcia-Bolao I. [Effect of the left ventricular pacing site on echocardiographic parameters of ventricular dyssynchrony in patients receiving cardiac resynchronization therapy]. Rev Esp Cardiol. 2004 Feb;57(2):138-45. Spanish. — View Citation

Mittal S, Nair D, Padanilam BJ, Ciuffo A, Gupta N, Gallagher P, Goldner B, Hammill EF, Wold N, Stein K, Burke M. Performance of Anatomically Designed Quadripolar Left Ventricular Leads: Results from the NAVIGATE X4 Clinical Trial. J Cardiovasc Electrophysiol. 2016 Oct;27(10):1199-1205. doi: 10.1111/jce.13044. Epub 2016 Aug 19. — View Citation

O'Brien T, Park MS, Youn JC, Chung ES. The Past, Present and Future of Cardiac Resynchronization Therapy. Korean Circ J. 2019 May;49(5):384-399. doi: 10.4070/kcj.2019.0114. — View Citation

Okamura H. Up-to-date cardiac resynchronization therapy. J Gen Fam Med. 2017 May 17;18(5):195-199. doi: 10.1002/jgf2.24. eCollection 2017 Oct. — View Citation

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20. No abstract available. Erratum In: Eur Heart J. 2016 Dec 30;: — View Citation

Tomassoni G, Baker J, Corbisiero R, Love C, Martin D, Niazi I, Sheppard R, Worley S, Beau S, Greer GS, Aryana A, Cao M, Harbert N, Zhang S; Promote(R) Q CRT-D and Quartet(R) Left Ventricular Heart Lead Study Group. Postoperative performance of the Quartet(R) left ventricular heart lead. J Cardiovasc Electrophysiol. 2013 Apr;24(4):449-56. doi: 10.1111/jce.12065. Epub 2013 Jan 22. — View Citation

Umar F, Taylor RJ, Stegemann B, Marshall H, Flannigan S, Lencioni M, De Bono J, Griffith M, Leyva F. Haemodynamic effects of cardiac resynchronization therapy using single-vein, three-pole, multipoint left ventricular pacing in patients with ischaemic cardiomyopathy and a left ventricular free wall scar: the MAESTRO study. Europace. 2016 Aug;18(8):1227-34. doi: 10.1093/europace/euv396. Epub 2015 Dec 30. — View Citation

Zeitler EP, Friedman DJ, Daubert JP, Al-Khatib SM, Solomon SD, Biton Y, McNitt S, Zareba W, Moss AJ, Kutyifa V. Multiple Comorbidities and Response to Cardiac Resynchronization Therapy: MADIT-CRT Long-Term Follow-Up. J Am Coll Cardiol. 2017 May 16;69(19):2369-2379. doi: 10.1016/j.jacc.2017.03.531. — View Citation

* Note: There are 18 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Axone 4LV implantation success rate		At implant, preferably within 15 days of enrollment
Other	Implantation duration		At implant, preferably within 15 days of enrollment
Other	Fluoroscopy time	Fluoroscopy time is measured in minutes	At implant, preferably within 15 days of enrollment
Other	Fluoroscopy dose	Fluoroscopy dose is measured using dose area product (Gray.cm^2)	At implant, preferably within 15 days of enrollment
Other	Axone system handling assessment	Implanters will be asked to fill in a handling questionnaire and record observations related to the use of the Axone system.	At implant, preferably within 15 days of enrollment
Other	Axone implanters' learning curve	This endpoint will be based on fluoroscopy time for implantation. The effect of removing the 1st, 2nd, 3rd, etc implanted subjects on mean fluoroscopy time (per implanter and per site) will be calculated.	At implant, preferably within 15 days of enrollment
Other	Number of excitable myocardium areas at implant	"Excitable myocardium areas" are areas that can be paced by the implanted Axone 4LV lead.	At implant, preferably within 15 days of enrollment
Other	Effect of CRT therapy, in particular bizone pacing, on QRS parameters, at discharge and 6 months post implant	The effect of monozone and bizone CRT pacing on duration of QRS is measured in milliseconds.	At discharge, within 7 days of implant, and at 6 months
Other	Effect of CRT therapy, in particular bizone pacing, on Left Pre-Ejection Interval (LPEI), at discharge	LPEI (in milliseconds) is an electromechanical parameter that can be assessed using echocardiography.	At discharge, within 7 days of implant
Other	Axone 4LV lead pacing threshold	Pacing threshold is measured in Volts.	Discharge (within 7 days of implant), 6 weeks, 3 months, 6 months, 12 months, 24 months 36 months, 48 months
Other	Axone 4LV lead pacing impedance	Pacing impedance is measured in Ohms.	Discharge (within 7 days of implant), 6 weeks, 3 months, 6 months, 12 months, 24 months 36 months, 48 months
Other	Presence of phrenic nerve stimulation (PNS) with the Axone 4LV lead	The presence of PNS will be assessed at 10V using an external pacing system analyzer at implant, or at pacing threshold +2V at other visits.	Implant (preferably within 15 days of enrollment), discharge (within 7 days of implant), 6 weeks, 3 months, 6 months
Other	Axone 4LV lead programming	Lead programming will be reported using: (i) pacing amplitude (Volts), pulse width (milliseconds) and pacing vector(s) selected.	Discharge (within 7 days of implant), 6 weeks, 3 months, 6 months, 12 months, 24 months 36 months, 48 months
Other	Energy consumption associated with Axone 4LV lead	Energy will be calculated using the formula: E=(pacing amplitude^2 x pulse width)/impedance. Energy, pacing amplitude, pulse width and impedance are measured in Joules, Volts, milliseconds, and Ohms, respectively.	6 months
Other	Axone system-related annual complication-free rate	Definition of Axone system related complication is the same as for primary safety endpoint.	12 months, 24 months 36 months, 48 months
Other	Clinical response to CRT at 12 months post implant	Clinical response will be determined by looking at functional improvement, reverse remodelling, freedom from heart failure events, and rate of non-responders: (i) functional improvement is defined as improvement in =1 NYHA (New York Heart Association) class from baseline to 12 months.; (ii) reverse remodelling is a =12% increase in left ventricular end systolic volume index (LVESVi: LVESV [mL] and body surface area [m^2] will be combined to report LVESVi).; (iii) freedom from heart failure events is defined as an absence of death or HF hospitalization.; (iv) non-responders are all those who are not responders. A responder is defined as a subject that is not dead and who did not experience any HF hospitalization and that has a stable or improved NYHA class versus baseline.	12 months
Primary	Safety co-primary endpoint, defined as Axone system related complication free rate at 6 months post implant	A complication is defined as any Serious Adverse Device Effect (SADE) resulting in death or requiring invasive intervention. Safety co-primary endpoint assessment will be based on independent event adjudication by a Clinical Event Committee (CEC).	6 months
Primary	Performance co-primary endpoint, defined as LV pacing success rate at 6 months post implant	LV pacing success is defined as at least one LV pacing vector with: Pacing Threshold (PT) = 3.5V at 1ms pulse width, and; No phrenic nerve stimulation at PT+2V / 1ms pulse width.	6 months
Secondary	Bizone LV pacing success rate at 6 months post implant	Bizone LV pacing success is defined as two distant pacing vectors with: A Pacing Threshold (PT) = 3.5V at 1ms pulse width, and; No phrenic nerve stimulation at PT +2V / 1ms pulse width. Two pacing vectors are considered distant when cathode electrodes are separated by at least 30 mm.	6 months